Chaoqun grew up in Ningbo, a coastal city in eastern China, and earned her Ph.D. in Biomedical Sciences at the University of Wyoming. Since joining the X-lab, she has worked on multiple projects, with a primary focus on β2-adrenergic receptor signaling crosstalk in cardiac pathological remodeling. She is currently investigating the regulation of thyroid hormone and mechanisms underlying septic heart injury. Outside of research, she enjoys hiking and photography, capturing nature during her hikes, as well as exploring different cultures through travel.
Amr is a MD/PhD from Egypt. He is a dedicated father with two wonderful little ones. Before joining X-lab, Amr is an experience clinical laboratory professional, specializing in ELISA based assay of biomarkers.
In X-lab, Amr is working on nongenomic actions of thyroid hormones and the impacts on cardiac cAMP-PKA pathway in the heart.
Wen has traveled around the world. After finishing her BS and MS in Shanghai, she won a National Scholarship and moved to pursue her PhD training in Hannover, Germany. She then joined X-lab at UCDavis/UCLA.
Wen is taking a very challenging project to study nuclear structure and gene regulation in adult myocytes and its implications in cardiac development and regeneration in heart failure. Outside the lab, she enjoys going to the gym and traveling.
Ning is a native in Beijing. He obtained his PhD in Peking University and currently is a visiting reseracher from Beijing Friendship Hospital, Capital Medical University in Beijing, where he holds an assistant professor equivalent title. He focuses on the cardiac injury mechanisms for receptor autoantibodies. Outside of the lab, Ning enjoys the time with his family.
In X-lab, he studies the novel regulation role of SAP97 in LTCC as well as cardiac remodeling in ischemic hearts.
Damini completed her PhD in Biochemistry in India and has done postdoctoral work at UC Merced and Duke. At UCLA, she is studying GPCR-targeted PROTACs and how amyloid peptides interact with the β2-adrenergic receptor. She is excited to explore new directions in GPCR pharmacology.